ANTI-CTHRC1 FUSION PROTEINS AND METHODS OF USING THE SAME

Abstract: the present invention is directed to anti-cthrc1 fusion proteins, compositions comprising the same, and methods of using such anti-cthrc1 fusion proteins and compositions for the prevention and/or treatment of cancer. wherein anti-cthrc1 fusion proteins comprise a first domain comprising a cthrc1 binding moiety; and a second domain comprising a t cell engager; preferably wherein the t cell engager comprises a ligand for a receptor expressed on a t cell.

Inventor(s): Sam Cooper, Christopher Harvey, Michael Briskin

CPC Classification: C07K16/18 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250215070